Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Shares Outstanding (2021 - 2025)

Prime Medicine's Shares Outstanding history spans 5 years, with the latest figure at $180.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 37.63% year-over-year to $180.5 million; the TTM value through Dec 2025 reached $180.5 million, up 37.63%, while the annual FY2025 figure was $180.5 million, 37.63% up from the prior year.
  • Shares Outstanding reached $180.5 million in Q4 2025 per PRME's latest filing, roughly flat from $180.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $180.5 million in Q4 2025 to a low of $32.4 million in Q3 2021.
  • Average Shares Outstanding over 5 years is $98.9 million, with a median of $97.4 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: skyrocketed 199.9% in 2022, then rose 0.17% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $32.4 million in 2021, then surged by 199.9% to $97.2 million in 2022, then increased by 0.17% to $97.4 million in 2023, then skyrocketed by 34.69% to $131.2 million in 2024, then skyrocketed by 37.63% to $180.5 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Shares Outstanding are $180.5 million (Q4 2025), $180.3 million (Q3 2025), and $134.5 million (Q2 2025).